ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / OABI
NRC (67) ABSI (45) MXCT (35) ICLR (71) ⌘ Pro Terminal →

OmniAb Inc. (OABI) — RQD Stock Rating Cockpit

$5.11 -2.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.08

OmniAb Inc. (OABI) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $760.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OABI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OABI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, OmniAb Inc. (NASDAQ: OABI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.11 (-2.29% 1D, market cap $760.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OABI ranks #433 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OABI compare to NRC and ABSI in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), OABI carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.6%. By comparison, NRC (NRC Health) holds a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M) and ABSI (Absci Corporation) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.08B). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OABI?
▼

Per OABI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001846253), OmniAb Inc. generated $18.7M in revenue (-29.3% YoY), -$64.8M in net income, and -$37.0M in free cash flow against $300.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.08 (-0.60%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D-
Cash (9)Whales (16)SEC (8)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
$6 Bull$5 Base$4 Bear
📬 FREE OABI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OABI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY OABI SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (36% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$4.77-1.7% Next Q
Q2 (-2Q)
39
Grade E$4.69-1.7% Next Q
Q3 (-1Q)
41
Grade D$4.61+10.8% Next Q
Current
44
Grade D$5.11-6.5% Hist 90D α
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OABI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OABI currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.67) and Max Pain ($5.37) forces dealer call-delta covering toward $5.70.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OABI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OABI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
6130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
12.19>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE92% OF RANGE
L: $1$5.11H: $5
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on OABI

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

-22.6% ROIC with 42.0% gross margin and -4.87% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 12.19 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (45)

19/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like OABI
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OABI)

  • ✓Walkthrough of OABI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OABI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +262.41%⚡ TESTING RESISTANCE
2026-11-02O $5.28H $5.28L $5.11C $5.11VOL 1.68M
RES: $5.41SUP: $2.51SMA50: $4.67SMA200: $2.72
$5.72$4.53$3.35$2.17$0.98RES $5.41SUP $2.51$5.112026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OABI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OABI Butterfly Map → + Track OABI →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -29.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OABI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OABI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OABI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OABI)

Health Care Rank #433 of 1016 ⚔️ NRC vs OABI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OABI vs. NRC, ABSI, MXCT, ICLR)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, OmniAb Inc. (OABI) ranks #433 by composite RQD confidence (44/100, grade D) and #392 by equity capitalization ($760.4M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. ICLR currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with OABI at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OABI ACTIVE
OmniAb Inc.
D 44/100 — — -22.6% -2.29% $760.4M Benchmark Subject
NRC
NRC Health
C+ 67/100 44.8x — 21.0% +1.45% $519.6M /nrc-vs-oabi →
ABSI
Absci Corporation
D 45/100 — — -35.0% -8.02% $2.08B /absi-vs-oabi →
MXCT
MaxCyte Inc.
D- 35/100 — 96.0% -27.1% -8.09% $178.5M /mxct-vs-oabi →
ICLR
ICON plc
B- 71/100 71.9x — 3.1% -1.91% $16.50B /iclr-vs-oabi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001846253

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OmniAb Inc. (OABI) reported GAAP revenue of $18.7M (-29.3% vs. FY2024 revenue of $26.4M , and -45.4% cumulative change since FY2023) , GAAP net income of -$64.8M, operating cash flow of -$36.5M, and free cash flow of -$37.0M (+10.9% YoY). On the balance sheet, OABI closed FY2025 with $300.9M in total assets against $0 in total debt (Altman Z-Score: 12.19, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $18.7M -$64.8M -$36.5M -$37.0M $300.9M —
FY2024 (FY) 2024-12-31 $26.4M -$62.0M -$39.7M -$41.5M $325.6M —
FY2023 (FY) 2023-12-31 $34.2M -$50.6M $2.3M $2.3M — —

3. OABI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OABI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, OmniAb Inc. (NASDAQ: OABI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.11 (-2.29% 1D, market cap $760.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OABI ranks #433 in composite RQD confidence.

How does OABI compare to NRC and ABSI in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), OABI carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.6%. By comparison, NRC (NRC Health) holds a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M) and ABSI (Absci Corporation) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.08B). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OABI?

Per OABI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001846253), OmniAb Inc. generated $18.7M in revenue (-29.3% YoY), -$64.8M in net income, and -$37.0M in free cash flow against $300.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OABI trading relative to its 50-day, 200-day, and 52-week technical levels?

OABI last traded at $5.11 (-2.29% on volume of 2,114,034 shares), positioning the stock +9.42% above its 50-day simple moving average ($4.67) and +87.87% above its 200-day simple moving average ($2.72). Across its 52-week range of $1.30 to $5.43, OABI sits at the 92.3% percentile with a 14-day RSI of 61.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.47 to $5.75).

OABI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell OABI stock right now?

OmniAb Inc. (OABI) currently earns a Roarable Rating of D (Sell — SELL) with 44/100 RQD Confidence. Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.

What is OABI's 12-month price target and RQD AI Jury consensus?

OABI's 12-month base price target is $4.79 (range $3.74 to $5.7), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: OABI RQD Cockpit OABI 12M Forecast OABI Earnings & Move OABI Dividends & DRIP OABI Insiders & 13F OABI Whale Options OABI Profit Sankey OABI News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

OABI — OmniAb Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:33:11Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, OABI scores 44 out of 100 (grade D; verdict "Roarable Sell — Underperform / Distribution Warning"). The five pillars break down as follows:

  • Fundamental Cash Engine: 9 / 20. Per the RQD rating, this pillar reflects ROIC of -22.6% and an FCF yield of -4.87%. For an investor, negative returns on invested capital and negative free-cash-flow yield mean the business is currently consuming rather than generating capital relative to its value.
  • Whale 13F Flow: 16 / 20. Per the RQD rating, this is the strongest pillar, described as reflecting institutional accumulation and options positioning. This is the one area where the rating signals constructive positioning, though the underlying 13F and options detail is not itemized in the source data.
  • Insider Conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow, and scores very low. For a prospective investor this is a meaningful caution flag, since the insider-flow signal is weak.
  • Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. The stock moves with the market and carries sector-level exposure, without a clear defensive or regime-favored profile.
  • Forensic Balance Sheet: 8 / 20. Per the RQD rating, the Altman Z-Score is 12.19, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. The high Z-Score points to low near-term bankruptcy risk, but the weak Piotroski score signals poor fundamental quality trends.

Taken together, the investment case rests on institutional interest and a solid balance-sheet cushion, offset by persistent operating losses, weak insider signals, and low fundamental quality. Upside depends on the business reaching cash-flow breakeven; the valuation tradeoff is that the current price reflects a company not yet generating positive returns, so the stock trades on future expectations rather than present earnings.

Business

OmniAb Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Commercial Physical & Biological Resarch industry. The source data does not describe its products, customers, or revenue model beyond its reported revenue figures. Market capitalization is listed as $0.8B in the company profile.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$18.7M$-69.0M$-64.8MN/A$-37.0M$25.5MN/A
FY 2024$26.4M$-74.5M$-62.0MN/A$-41.5M$27.6MN/A
FY 2023$34.2M$-69.4M$-50.6MN/A$2.3MN/AN/A

Revenue declined from $34.2M (FY 2023) to $26.4M (FY 2024) to $18.7M (FY 2025), while net losses persisted in every reported year. Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -22.6%. Per the RQD rating, the Altman Z-Score is 12.19 (suggesting low distress risk) and the Piotroski F-Score is 2/9 (indicating weak fundamentals), with Debt/Equity at 0.5. Reported cash declined from $27.6M to $25.5M over the most recent year.

Recent Catalysts & News Wire Analysis

Recent headlines (per the news feed) include a Yahoo Finance item titled with a rating upgrade to Buy, a Seeking Alpha piece describing a "self-funding option book" across 433 partner programs, and a ChartMill report describing a Q3 2026 revenue beat and raised guidance offset by sell-the-news pressure. Other items include Yahoo Finance coverage of Q3 results focused on cash progress, and Moomoo options and forum pages. Several items are tagged as catalysts (green) and others as market wire (yellow).

Risk watch items: the news wire reports selling pressure following a revenue beat, and cash-progress framing signals that cash generation remains a central question. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Open Questions

  • What are OmniAb's products, customers, and revenue sources, given that the source data provides only financial totals and a sector classification?
  • What is the path to positive operating cash flow, given operating losses in every reported year and FCF of $-37.0M in FY 2025?
  • Why did reported revenue decline across FY 2023–FY 2025, and what is driving the Q3 2026 revenue beat referenced in the news feed?
  • What are the specific 13F, options, and insider trades underlying the whale-flow and insider-conviction pillar scores?
  • What are the EPS, P/E, and EV/EBITDA figures, which are absent from the source data and would be needed to value the stock against earnings?

OABI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for OmniAb Inc. (OABI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OABI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OABI Bull vs. Bear Conversation Board — What's Your Call at $5.11?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OABI 🐻 67% BEARISH CONVICTION
1. Pick Your Side on OABI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.60 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is OABI (D • RQD 44/100) a Buy at $5.23?

Welcome to the OABI (OmniAb Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.24 (-18.9%)
Spot @ $5.23

Pump the brakes on OABI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on OABI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless OmniAb Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.64 (+27.0%)
Spot @ $5.23

OABI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on OABI, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $5.23 (52-wk range $1.30 - $5.43), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%